The purpose of this study is to determine the safety and feasibility of adding isatuximab to
standard of care therapies in patients who will receive a lung transplant, but have
significant antibodies against the donor (desensitization), or patients who have previously
received a lung transplant and develop antibodies against the donor (antibody-mediated
rejection, AMR). The study will compare the impact of isatuximab on the recurrence of
antibodies after they have been removed from the blood by a process known as plasmapheresis
that is standard of care for this condition. The use of isatuximab in lung transplant
recipients is investigational, meaning it is not Food and Drug Administration (FDA) approved
for use in lung transplant recipients. This study is a pilot study investigating the
feasibility and safety of isatuximab in lung transplant patients. Isatuximab is an FDA
approved drug indicated for the treatment of multiple myeloma. It may also be useful for
transplant recipients with antibodies against the donor because it eliminates the cells that
make antibodies.